ABSTRACT
Biological drugs, such as proteins and immunogens, are increasingly used to treat various diseases, including tumors and autoimmune diseases, and biological molecules have almost completely replaced synthetic drugs in rheumatology. Although biological treatments such as anti-tumor necrosis factor (TNF) drugs seem to be quite safe, they cause some undesirable effects, such as the onset of infections due to weakening of the immune system. Given the biological nature of these drugs, they might be recognized as extraneous; this would induce an immune reaction that neutralizes their effectiveness or lead to more serious consequences. Laboratories play a pivotal role in appropriate therapeutic management. The aim of this review was to underline the production of anti-drug antibodies during treatment with biological drugs and highlight the role of laboratories in ensuring appropriate use of these drugs.
Subject(s)
Biological Factors/blood , Drug Monitoring , Adalimumab/blood , Adalimumab/immunology , Adalimumab/therapeutic use , Antibodies, Monoclonal/blood , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/therapeutic use , Arthritis, Rheumatoid/drug therapy , Biological Factors/immunology , Biological Factors/therapeutic use , Biosimilar Pharmaceuticals/blood , Biosimilar Pharmaceuticals/therapeutic use , HumansABSTRACT
Objective: To establish evidence-based and experts' opinion filtered statements on the optimal treatment choice between cycling (switch) and changing mode of action strategies (swap) in RA patients failing TNF inhibitors (TNFis). Methods: The relevant question (switch vs swap) was rephrased into a research question according to the population, intervention, comparison and outcome (PICO) strategy, considering all the available scientific evidence published from the 2013 EULAR set of recommendations up to mid-January 2016. Final statements derived from the retrieved scientific evidence and experts' consensus, with eventual rephrasing through a Delphi method during a national consensus of Italian rheumatologists. Results: From a total of 365 records, 12 studies were finally included. The final statements argued that, until head-to-head comparison data are available, switch and swap can be still considered suitable strategies in RA patients failing first TNFi, even though some data seem to lend more support to a different mode of action-targeted strategy. Conclusion: After failure of first TNFi course, switch and swap can be currently considered as alternative suitable approaches in RA patients.
Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Consensus , Evidence-Based Medicine/methods , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Delphi Technique , Humans , ItalyABSTRACT
OBJECTIVES: Inflammatory arthritis needs infectious disease screening before starting a biologic agent, however, few data are known about migrant patients, who represent a peculiar population which requires a multidisciplinary approach among international health specialists and should also be considered by health authorities. For this reason, the Italian and Spanish Societies of Rheumatology (SIR and SER) and Tropical Medicine (SIMET and SEMTSI) promoted a multidisciplinary task force in order to produce specific recommendations about screening and advices to be considered in migrant patients with inflammatory arthritis candidate to receive biological therapy, according to their geographical origin. METHODS: The experts provided a prioritised list of research questions and the eligible spectrum of inflammatory arthritis, biologic drugs and infectious disease were defined in order to perform a systematic literature review. A search was made in Medline, Embase and Cochrane library, updated to March 2015. Ubiquitous infections and HBV, HCV, HIV and tuberculosis that are already considered in national and international recommendations, were not included. The strength of each recommendation was determined. RESULTS: The task force members agreed on 7 overarching principles. The risk of reactivation of selected potentially latent infectious disease was addressed in migrants with inflammatory arthritis candidates for biologics was considered and 15 potentially relevant infections were identified. CONCLUSIONS: Fifteen disease-specific recommendations were formulated on the basis of high level of agreement among the experts panel.
Subject(s)
Advisory Committees , Arthritis, Rheumatoid/drug therapy , Biological Products/therapeutic use , Communicable Diseases/diagnosis , Emigrants and Immigrants , Emigration and Immigration , Infectious Disease Medicine/standards , Mass Screening/standards , Rheumatology/standards , Societies, Medical , Arthritis, Rheumatoid/diagnosis , Arthritis, Rheumatoid/ethnology , Biological Products/adverse effects , Communicable Diseases/ethnology , Consensus , Evidence-Based Medicine/standards , Humans , Italy/epidemiology , Mass Screening/methods , Predictive Value of Tests , Risk Assessment , Risk Factors , Spain/epidemiologyABSTRACT
The aim of this study was to establish consensus for potential early symptomatic knee osteoarthritis (ESKOA) clinical definition and referral criteria from primary care to rheumatologists, based on available data from literature and a qualitative approach, in order to perform studies on patients fulfilling such criteria and to validate the obtained ESKOA definition. A complex methodological approach was followed including: (1) three focus groups (FG), including expert clinicians, researchers and patients; (2) a systematic literature review (SLR); (3) two discussion groups followed by a Delphi survey. FG and SLR were performed in parallel to inform discussion groups in order to identify relevant constructs to be included in the modified Delphi survey. ESKOA is defined in the presence of: (a) two mandatory symptoms (knee pain in the absence of any recent trauma or injury and very short joint stiffness, lasting for less than 10 min, when starting movement) even in the absence of risk factors, or (b) knee pain, and 1 or 2 risk factors or (c) three or more risk factors in the presence of at least one mandatory symptom, with symptoms lasting less than 6 months. These criteria are applicable in the absence of active inflammatory arthritis, generalized pain, Kellgren-Lawrence grade >0, any recent knee trauma or injury, and age lower than 40 years. Knee pain in the absence of any recent trauma lasting for less than 6 months was considered as the referral criterion to the rheumatologist for the suspicion of ESKOA. This consensus process has identified provisional clinical definition of ESKOA and defined potential referral criterion to rheumatologist, in order to test ESKOA obtained definition in prospective validation studies.
Subject(s)
Consensus , Early Diagnosis , Osteoarthritis, Knee/diagnosis , Referral and Consultation/standards , Delphi Technique , Female , Focus Groups , Humans , Italy , Male , Osteoarthritis, Knee/physiopathology , Qualitative Research , Rheumatology , Risk Factors , Societies, Medical , Symptom Assessment , Time FactorsABSTRACT
BACKGROUND: Systemic lupus erythematosus (SLE) is an autoimmune disease with a high degree of variability at onset, making it difficult to reach a correct and prompt diagnosis. OBJECTIVES: To present the difficulties faced by the clinician in making a SLE diagnosis, based on the characteristics at study entry of an Italian cohort of SLE patients with recent onset as compared to two similar cohorts. METHODS: Beginning on 1 January 2012 all patients with a diagnosis of SLE (1997 ACR criteria) and disease duration of less than 12 months were consecutively enrolled in a multicenter prospective study. Information on clinical and serological characteristics was collected at study entry and every 6 months thereafter. RESULTS: Our cohort consisted of 122 patients, of whom 103 were females. Among the manifestations included in the 1997 American College of Rheumatology (ACR) criteria, cutaneous, articular and hematologic symptoms were the most prevalent symptoms at study entry. CONCLUSIONS: Data from the literature confirm that the diagnosis of SLE is challenging, and that SLE is a severe disease even at onset when a prompt diagnosis is necessary for initiating the appropriate therapy.
Subject(s)
Antirheumatic Agents/therapeutic use , Lupus Erythematosus, Systemic , Quality of Life , Adult , Age of Onset , Early Diagnosis , Female , Humans , Italy/epidemiology , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/drug therapy , Lupus Erythematosus, Systemic/epidemiology , Lupus Erythematosus, Systemic/immunology , Lupus Erythematosus, Systemic/physiopathology , Lupus Erythematosus, Systemic/psychology , Male , Middle Aged , Prevalence , Prognosis , Prospective Studies , Severity of Illness Index , Symptom Assessment/methods , Symptom Assessment/statistics & numerical dataABSTRACT
BACKGROUND: The aim was to establish how patients experience the impact of spondyloarthritis (SpA) on work disability and working life. METHODS: The survey was performed in 17/20 regions in Italy (1 January to 31 March 2013). A multiple-choice questionnaire was published on the official website of the sponsor - the National Association of Rheumatic Patients (ANMAR) - and hard-copies were distributed at outpatient clinics for rheumatic patients. RESULTS: Respondents (n = 770) were of both sexes (56 % men), educated (62 % at high school or more), of working age (75 % aged ≤60 years), and affected by SpA. The most common types diagnosed were ankylosing spondylitis (AS) (39 %) and psoriatic arthritis (PsA) (36 %). Respondents were working full-time (45 %), part-time (8 %) or had retired (22 %); 15 % were unemployed (for reasons linked to the disease or for other reasons, students or housewives). Patients reported disability (39 %), were receiving disability benefits (34 %), were experiencing important limitations that were hindering their professional development/career (36 %) and some had to change/leave their job or lost it because of SpA (21 %). Employed respondents (n = 383) had worked on average 32.2 h in the last 7 days. More hours of work were lost over the last 7 days due to SpA (2.39 h vs 1.67 h). The indirect costs of the disease amounted to 106/week for patients reporting well-being/good physical conditions/improvement and 216/week for those reporting permanent impairment. CONCLUSIONS: Most patients were in the midst of their productive years and were experiencing considerable difficulties in carrying out their job because of the disease: half of them reported disability and one third were experiencing important limitations in their career perspective.
Subject(s)
Absenteeism , Arthritis, Psoriatic/complications , Disability Evaluation , Quality of Life , Spondylitis, Ankylosing/complications , Adult , Aged , Employment/statistics & numerical data , Female , Humans , Italy , Male , Middle Aged , Self Report , Surveys and QuestionnairesABSTRACT
UNLABELLED: The patients' adherence to osteoporosis treatments is low. In our study population a history of osteoporotic fractures was associated to better compliance and persistence; however, a 12-month randomized study carried out on 816 osteoporotic women showed that providing the patients with their individual fracture risk information did not prove effective. PURPOSE: Several drugs are currently available for the treatment of osteoporosis, but the patients' compliance and persistence with these treatments are low. This study aimed to both analyze the adherence to oral osteoporosis medications among Italian osteoporotic patients (cross-sectional study) and evaluate if providing patients with their individual fracture risk information may improve compliance and persistence (prospective study). METHODS: A total of 3379 osteoporotic patients referred as outpatients for a visit 1 year after receiving a prescription of oral osteoporosis medications for the first time, were enrolled for the retrospective study. Moreover, 816 postmenopausal women receiving an oral prescription for osteoporosis for the first time, were randomized into two groups: group 1 (managed according to standard clinical practice) and group 2 (managed with greater patient involvement and information on the individual risk of major osteoporotic fractures calculated by DeFRA algorithm). RESULTS: In the retrospective study, a history of osteoporotic fractures, the frequency of drug administration and a condition of being overweight/obese had a significant influence on both compliance and persistence. Of the 816 patients enrolled in the longitudinal study, 731 (374 of group 1 and 357 of group 2) attended the 1 year follow-up visit. The percentage of women with high compliance or persistence was greater in group 2 (64.2 vs. 58.1 % and 66.8 vs. 62.6 %, respectively), but without reaching any statistical significance. CONCLUSIONS: Although providing the patients with their individual fracture risk information was not statistically effective, further studies on additional interventions able to improve the patients' perceived risk of fracture are warranted.
Subject(s)
Bone Density Conservation Agents/therapeutic use , Medication Adherence , Osteoporosis, Postmenopausal/drug therapy , Osteoporotic Fractures/prevention & control , Administration, Oral , Aged , Cross-Sectional Studies , Female , Humans , Middle Aged , Osteoporotic Fractures/etiology , Prospective Studies , Retrospective Studies , RiskABSTRACT
OBJECTIVE: To develop a new composite disease activity score for gout and provide its first validation. METHODS: Disease activity has been defined as the ongoing presence of urate deposits that lead to acute arthritis and joint damage. Every measure for each Outcome Measures in Rheumatology core domain was considered. A 3-step approach (factor analysis, linear discriminant analysis, and linear regression) was applied to derive the Gout Activity Score (GAS). Decision to change treatment or 6-month flare count were used as the surrogate criteria of high disease activity. Baseline and 12-month followup data of 446 patients included in the Kick-Off of the Italian Network for Gout cohort were used. Construct- and criterion-related validity were tested. External validation on an independent sample is reported. RESULTS: Factor analysis identified 5 factors: patient-reported outcomes, joint examination, flares, tophi, and serum uric acid (sUA). Discriminant function analysis resulted in a correct classification of 79%. Linear regression analysis identified a first candidate GAS including 12-month flare count, sUA, visual analog scale (VAS) of pain, VAS global activity assessment, swollen and tender joint counts, and a cumulative measure of tophi. Alternative scores were also developed. The developed GAS demonstrated a good correlation with functional disability (criterion validity) and discrimination between patient- and physician-reported measures of active disease (construct validity). The results were reproduced in the external sample. CONCLUSION: This study developed and validated a composite measure of disease activity in gout. Further testing is required to confirm its generalizability, responsiveness, and usefulness in assisting with clinical decisions.
Subject(s)
Disease Progression , Gout/diagnosis , Severity of Illness Index , Aged , Arthralgia/etiology , Arthralgia/pathology , Factor Analysis, Statistical , Female , Follow-Up Studies , Gout/drug therapy , Gout/pathology , Humans , Joints/pathology , Linear Models , Male , Middle Aged , Pain Measurement , Patient Reported Outcome Measures , Regression Analysis , Reproducibility of Results , Uric Acid/bloodABSTRACT
OBJECTIVES: To develop and validate a new algorithm to identify patients with rheumatoid arthritis (RA) and estimate disease prevalence using administrative health databases (AHDs) of the Italian Lombardy region. DESIGN: Case-control and cohort diagnostic accuracy study. METHODS: In a randomly selected sample of 827 patients drawn from a tertiary rheumatology centre (training set), clinically validated diagnoses were linked to administrative data including diagnostic codes and drug prescriptions. An algorithm in steps of decreasing specificity was developed and its accuracy assessed calculating sensitivity/specificity, positive predictive value (PPV)/negative predictive value, with corresponding CIs. The algorithm was applied to two validating sets: 106 patients from a secondary rheumatology centre and 6087 participants from the primary care. Alternative algorithms were developed to increase PPV at population level. Crude and adjusted prevalence estimates taking into account algorithm misclassification rates were obtained for the Lombardy region. RESULTS: The algorithms included: RA certification by a rheumatologist, certification for other autoimmune diseases by specialists, RA code in the hospital discharge form, prescription of disease-modifying antirheumatic drugs and oral glucocorticoids. In the training set, a four-step algorithm identified clinically diagnosed RA cases with a sensitivity of 96.3 (95% CI 93.6 to 98.2) and a specificity of 90.3 (87.4 to 92.7). Both external validations showed highly consistent results. More specific algorithms achieved >80% PPV at the population level. The crude RA prevalence in Lombardy was 0.52%, and estimates adjusted for misclassification ranged from 0.31% (95% CI 0.14% to 0.42%) to 0.37% (0.25% to 0.47%). CONCLUSIONS: AHDs are valuable tools for the identification of RA cases at the population level, and allow estimation of disease prevalence and to select retrospective cohorts.
Subject(s)
Algorithms , Arthritis, Rheumatoid/diagnosis , Databases, Factual/statistics & numerical data , Medical Records Systems, Computerized/statistics & numerical data , Adult , Aged , Aged, 80 and over , Arthritis, Rheumatoid/epidemiology , Case-Control Studies , Cohort Studies , Female , Humans , Italy/epidemiology , Male , Medical Record Linkage , Middle Aged , Prevalence , Rheumatology/statistics & numerical data , Sensitivity and SpecificitySubject(s)
Heart Diseases/etiology , Lupus Erythematosus, Systemic/complications , Female , Humans , MaleSubject(s)
Lupus Erythematosus, Systemic/complications , Peritonitis/etiology , Adult , Ascites/etiology , Drug Therapy, Combination , Female , Humans , Immunosuppressive Agents/therapeutic use , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/drug therapy , Peritonitis/diagnosis , Peritonitis/drug therapy , Recurrence , Remission Induction , Risk Factors , Time Factors , Treatment OutcomeSubject(s)
Gastrointestinal Agents/therapeutic use , Gastrointestinal Hemorrhage/etiology , Octreotide/therapeutic use , von Willebrand Disease, Type 2/drug therapy , Aged , Angiodysplasia/diagnosis , Aortic Valve Stenosis/diagnosis , Gastrointestinal Hemorrhage/drug therapy , Humans , Male , Syndrome , von Willebrand Disease, Type 2/diagnosisSubject(s)
Cardiomegaly/diagnostic imaging , Coronary Aneurysm/etiology , Lupus Erythematosus, Systemic/complications , Tuberculosis, Pulmonary/complications , Adult , Confounding Factors, Epidemiologic , Coronary Aneurysm/diagnosis , Coronary Aneurysm/diagnostic imaging , Coronary Angiography , Diagnosis, Differential , Echocardiography , Female , Heart Failure/etiology , Heart Failure/therapy , Humans , Lung/diagnostic imaging , Lung/pathology , Mitral Valve Insufficiency/diagnostic imaging , Tuberculosis, Pulmonary/diagnosis , Tuberculosis, Pulmonary/therapyABSTRACT
Musculoskeletal diseases are tile most frequent cause of pain in the working population. Rheumatic diseases are chronic illnesses, cause of functional impairnment, relevant working disability and absence from work; however, affected patients maintain a significant functional ability. In this context, the "Fit for work" project, operating in Italy since 2012, promotes the management of chronic musculoskeletal conditions through the realization, also in our country, of a rheumatic medical assistance network in behalf of workers affected by rheumatic diseases and other musculoskeletal disabiliting conditions.
Subject(s)
Medical Assistance/organization & administration , National Health Programs/organization & administration , Occupational Health Services/organization & administration , Return to Work , Rheumatic Diseases/epidemiology , Absenteeism , Antirheumatic Agents/therapeutic use , Cost of Illness , Drugs, Investigational/therapeutic use , Humans , Italy , Musculoskeletal Diseases/epidemiology , Musculoskeletal Diseases/rehabilitation , Musculoskeletal Diseases/therapy , Occupational Medicine/organization & administration , Rheumatic Diseases/rehabilitation , Rheumatic Diseases/therapy , Socioeconomic Factors , Spain , Therapies, Investigational , Work Capacity EvaluationABSTRACT
INTRODUCTION: Gout is the most prevalent arthritis and significantly impacts on function and quality of life. Given that gout associates with disabling comorbid conditions, it is not clear whether such a complex of diseases accounts for the increased disability or if gout may play a role by itself. This study aims to evaluate the specific influence of gout and disease-related features on functional disability and health-related quality of life (HRQoL) in patients with gout followed in rheumatology clinics. METHODS: A random sample of patients was drawn from clinical registries of 30 rheumatology clinics across Italy. Sociodemographic, general health and gout-specific variables were collected. Functional disability and HRQoL were assessed by the health assessment questionnaire (HAQ) and the Physical and Mental Component Summary scores (PCS and MCS) of the Short Form-36 (SF-36). Crude and adjusted ordinal logistic and linear regression models were applied to investigate the specific contribution of different variables on HAQ and SF-36 scores. Results are presented as odds ratio (OR) or mean difference (MD) and 95% confidence intervals. RESULTS: Out of 446 patients with gout, 90% were males with a mean age of 63.9 years and median disease duration of 3.8 years; the majority of patients were overweight or obese, and with several comorbidities; 21.1% showed at least moderate disability; the PCS score was significantly lower than expected age- and gender-matched samples in the general population, while MCS score was not. After adjusting for potential sociodemographic and general-health confounders, gout-specific variables significantly impacted on HAQ, including polyarticular involvement OR 3.82 (1.63, 8.95), presence of tophi OR 1.92 (1.07, 3.43) and recent attacks OR 2.20 (1.27, 3.81). Consistent results were found for PCS. The impairment of PCS compared to the general population was limited to patients with features of chronic gout. MCS was only affected by recent attacks (MD -2.72 [-4.58, -0.86]) and corticosteroid treatment (-3.39 [-5.30,-1.48]). CONCLUSION: The data from the KING study confirm that gout impacts on disability and provide evidence for an independent association of gout and gout-related features with functional outcome and HRQoL. This result supports the need to improve specific treatment in gout.